WilliamDTapMD

Associate Member, Memorial Sloan Kettering Cancer Center

Overview of Dr. Tap

Dr. William Tap is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Sidney Kimmel Medical College at Thomas Jefferson University and has been in practice 17 years. Dr. Tap accepts several types of health insurance, listed below. He is one of 503 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
160 East 53rd Street
New York, NY 10022
Book by Phone+1(231) 515-5987

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
Vanderbilt University Medical CenterResidency, Internal Medicine, 2000 - 2003
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2000

Certifications & Licensure

CA State Medical License 2003 - Present
FL State Medical License 2021 - Present
NY State Medical License 2011 - 2026
NJ State Medical License 2020 - 2025
TN State Medical License 2002 - 2004
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2014
Top Doctors: New York Metro Area Castle Connolly, 2013-2014
America's Top Doctors for Cancer Castle Connolly, 2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Sorafenib and Dacarbazine in Soft Tissue Sarcoma Start of enrollment: 2009 Feb 01
Completed
Phase 2
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes Start of enrollment: 2009 Apr 01
Completed
Phase 2
Safety Study of PLX108-01 in Patients With Solid Tumors Start of enrollment: 2009 Oct 01
Completed
Phase 1
Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma Start of enrollment: 2009 Nov 01
Completed
Phase 2
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Start of enrollment: 2011 Aug 01
Terminated
Phase 1, Phase 2
A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma Start of enrollment: 2011 Sep 01
Completed
Phase 3
BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) Start of enrollment: 2014 Oct 02
Completed
Phase 1, Phase 2
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2015 Sep 14
COMPLETED
PHASE3
Join now to see all

Publications & Presentations

PubMed

Immunologic correlates in a CIC::DUX4 fusion-positive sarcoma responsive to dual immune checkpoint blockade.
Olayode O Babatunde, Sara Coca Membribes, Cristina Anthonescu, Martina Bradic, Bernard O'Malley
NPJ Precision Oncology. 2025-03-25
Phase I study of the mutant IDH1 inhibitor ivosidenib: long-term safety and clinical activity in patients with conventional chondrosarcoma.
William D Tap, Gregory M Cote, Howard Burris, Lia Gore, Anthony Elias
Clinical Cancer Research. 2025-03-18
Alternative driver pathways in peripheral nerve sheath tumors - including DICER1 and/or KRAS alterations.
Hsin-Yi Chang, Carla Saoud, Dianne Torrence, William Tap, Ping Chi
The Journal of Pathology. 2025-03-01

Lectures

ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced...
2019 ASCO Annual Meeting - 6/1/2019
Responder analysis of patient-reported outcomes measurement information system (PROMIS) physical function (PF) and worst stiffness among patients with tenosynovial gia...
2019 ASCO Annual Meeting - 6/1/2019
Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

FDA Approves Romvimza for Tenosynovial Giant Cell Tumor (TGCT)February 20th, 2025
FDA Grants Approval for Vimseltinib in Treatment of Tenosynovial Giant Cell Tumor (TGCT)February 19th, 2025
Peptomyc Announces the Beginning of a Phase 2 Clinical Trial of OMO-103 in Advanced OsteosarcomaJanuary 16th, 2025
Join now to see all

Insurance Accepted

BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
Health Net Oregon PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment